861905-22-8 Usage
Uses
Used in Pharmaceutical Industry:
Methyl 3-fluoro-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate is utilized as a key intermediate in the synthesis of new pharmaceutical compounds. Its unique structure and reactivity contribute to the development of biologically active molecules, which are essential for creating innovative drugs to treat various diseases and conditions.
Used in Agrochemical Industry:
In the agrochemical sector, Methyl 3-fluoro-4-Methyl-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)benzoate serves as a vital building block for the creation of new pesticides. Its properties allow for the synthesis of molecules with potential pesticidal activity, thereby contributing to the development of more effective and targeted crop protection agents.
Used in Organic Synthesis:
Methyl 3-fluoro-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate is employed as a reagent in organic synthesis processes, where it aids in the formation of complex molecular structures through carbon-carbon and carbon-heteroatom bond formations. This capability is crucial for the advancement of organic chemistry and the synthesis of a wide range of chemical products.
Check Digit Verification of cas no
The CAS Registry Mumber 861905-22-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,6,1,9,0 and 5 respectively; the second part has 2 digits, 2 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 861905-22:
(8*8)+(7*6)+(6*1)+(5*9)+(4*0)+(3*5)+(2*2)+(1*2)=178
178 % 10 = 8
So 861905-22-8 is a valid CAS Registry Number.
861905-22-8Relevant academic research and scientific papers
GLUCOSE SENSITIVE INSULIN DERIVATIVES
-
, (2020/10/20)
The present invention relates to novel insulin derivatives and their use in the treatment or prevention of medical conditions relating to diabetes. The insulin derivatives are glucose sensitive and display glucose-sensitive albumin binding. The invention
GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES
-
, (2019/05/30)
This invention relates to glucose-sensitive albumin-binding diboron conjugates. More particularly the invention provides novel diboron compounds, and in particular diboronate or diboroxole compounds, useful as intermediate compounds for the synthesis of diboron conjugates. The diboron compounds are characterized by formula (I), which is: R1-X-R2, and wherein "X" is a mono- to multiatomic linker and where R1 and R2, which may be identical or different, each represents a group of Formula (lla) or (IIb) Also described are diboron conjugates represented by the general Formula (I'), which is: R1'-X'-R2', in which either the moeities R1' or R2' or X' carry a drug that is covalently attached to the diboron compound.
N-(2, 2-DIMETHYLPROPYL) -6- (3-FLUORO-5- ( (3-ISOXAZOLYLAMINO) CARBONYL) -2-METHYLPHENY L) -3-PYRIDINECARBOXAMIDE
-
, (2010/11/25)
The present invention relates to a novel compound, processes for its preparation, compositions comprising the same and its use in the treatment of condition or diseases mediated by p38 kinase activity.
